{"id":2072,"date":"2021-08-14T14:35:22","date_gmt":"2021-08-14T14:35:22","guid":{"rendered":"http:\/\/wp.cov19longhaulfoundation.org\/?p=2072"},"modified":"2021-08-14T14:35:22","modified_gmt":"2021-08-14T14:35:22","slug":"ivermectin-for-covid-19-real-time-meta-analysis-of-63-studies","status":"publish","type":"post","link":"https:\/\/cov19longhaulfoundation.org\/?p=2072","title":{"rendered":"Ivermectin for COVID-19: real-time meta analysis of 63 studies"},"content":{"rendered":"\n

Authors: Covid Analysis<\/a>,\u00a0Aug 12, 2021<\/strong><\/a>,\u00a0Version 109<\/a>\u00a0\u2014\u00a0twitter personality response, added Together Trial<\/a>\u00a0(V1 Nov 26, 2020<\/a>)<\/p>\n\n\n\n

\u2022Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and prophylaxis<\/a> (RR 0.27 [0.16-0.44] and 0.14 [0.08-0.25]), with similar results after exclusion based sensitivity analysis<\/a>, restriction to peer-reviewed studies<\/a>, restriction to serious outcomes<\/a>, and restriction to Randomized Controlled Trials<\/a>.\u202261% and 96% lower mortality<\/a> is observed for early treatment and prophylaxis (RR 0.39 [0.17-0.90] and 0.04 [0.00-0.59]). Statistically significant improvements are seen for mortality<\/a>, hospitalization<\/a>, recovery<\/a>, cases<\/a>, and viral clearance<\/a>. 27 studies show statistically significant improvements in isolation.<\/p>\n\n\n\n

<\/td>Studies<\/em><\/td>Prophylaxis<\/a><\/em><\/td>Early treatment<\/a><\/em><\/td>Late treatment<\/a><\/em><\/td>Patients<\/em><\/td>Authors<\/em><\/td><\/tr>
All studies<\/a><\/td>63<\/td>86%<\/strong> [75\u201192%]<\/td>73%<\/strong> [56\u201184%]<\/td>40%<\/strong> [24\u201152%]<\/td>26,422<\/td>613<\/td><\/tr>
With exclusions<\/a><\/td>51<\/td>88%<\/strong> [76\u201194%]<\/td>76%<\/strong> [66\u201183%]<\/td>50%<\/strong> [28\u201165%]<\/td>18,907<\/td>525<\/td><\/tr>
Peer-reviewed<\/a><\/td>42<\/td>86%<\/strong> [73\u201193%]<\/td>75%<\/strong> [61\u201184%]<\/td>43%<\/strong> [21\u201159%]<\/td>16,455<\/td>436<\/td><\/tr>
Randomized Controlled Trials<\/a><\/td>31<\/td>84%<\/strong> [25\u201196%]<\/td>67%<\/strong> [54\u201176%]<\/td>30%<\/strong> [2\u201150%]<\/td>6,561<\/td>359<\/td><\/tr>
Mortality results<\/a><\/td>25<\/td>96%<\/strong> [41\u2011100%]<\/td>61%<\/strong> [10\u201183%]<\/td>53%<\/strong> [32\u201167%]<\/td>13,911<\/td>263<\/td><\/tr>
Percentage improvement with ivermectin treatment<\/em><\/td><\/tr><\/tbody><\/table>
Meta-Analysis of Studies for Ivermectin Effectiveness Against COVID-19<\/figcaption><\/figure>\n\n\n\n

\u2022The probability that an ineffective treatment generated results as positive as the 63 studies to date is estimated to be 1 in 1 trillion (p<\/em>\u00a0= 0.00000000000083).<\/p>\n\n\n\n

\u2022Heterogeneity<\/a>\u00a0arises from many factors including treatment delay, population, dose, and effect measured, and is low in specific cases, e.g., early treatment mortality.<\/p>\n\n\n\n

\u2022While\u00a0many treatments<\/a>\u00a0have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 29% of ivermectin studies show zero events in the treatment arm.<\/p>\n\n\n\n

\u2022Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. All practical, effective, and safe means should be used. Those denying the efficacy of treatments share responsibility for the increased risk of COVID-19 becoming endemic; and the increased mortality, morbidity, and collateral damage.<\/p>\n\n\n\n

\u2022The evidence base is\u00a0much larger<\/a>\u00a0and has much lower conflict of interest than typically used to approve drugs.\u2022All data to reproduce this paper and sources are in the\u00a0appendix<\/a>. <\/p>\n\n\n\n

See\u00a0[Bryant<\/a>,\u00a0Hariyanto<\/a>,\u00a0Hill<\/a>,\u00a0Kory<\/a>,\u00a0Lawrie<\/a>,\u00a0Nardelli<\/a>]<\/em>\u00a0for other meta analyses with similar results confirming effectiveness.\u00a000.250.50.7511.251.51.752+Kory et al.69%0.31 [0.20-0.47]Improvement, RR [CI]Hill et al.75%0.25 [0.12-0.52]Bryant et al.62%0.38 [0.19-0.73]Lawrie et al.83%0.17 [0.08-0.35]Nardelli et al.79%0.21 [0.11-0.36]Hariyanto et al.69%0.31 [0.15-0.62]WHO (OR)81%0.19 [0.09-0.36]ivmmeta61%0.39 [0.28-0.56]Ivermectin meta analysis mortality resultsivmmeta.com 8\/14\/21Lower RiskIncreased Risk<\/a><\/p>\n\n\n\n

Global adoption: 30%<\/a><\/a><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
Evidence base used for other COVID-19 approvals<\/em><\/td><\/tr>
Medication<\/td>Studies<\/td>Patients<\/td>Improvement<\/td><\/tr>
Budesonide (UK)<\/a><\/td>1<\/td>1,779<\/td>17%<\/td><\/tr>
Remdesivir (USA)<\/a><\/td>1<\/td>1,063<\/td>31%<\/td><\/tr>
Casiri\/imdevimab (USA)<\/a><\/td>1<\/td>799<\/td>66%<\/td><\/tr>
Ivermectin evidence<\/em><\/td>63<\/td>26,398<\/td>69% [60\u201175%]<\/td><\/tr><\/tbody><\/table>
Effectiveness of Other Medications Against COVID-19<\/figcaption><\/figure>\n\n\n\n

For More Information: https:\/\/ivmmeta.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Authors: Covid Analysis,\u00a0Aug 12, 2021,\u00a0Version 109\u00a0\u2014\u00a0twitter personality response, added Together Trial\u00a0(V1 Nov 26, 2020) \u2022Meta analysis using the most serious outcome reported shows 73% and 86% improvement for early treatment and […]<\/p>\n","protected":false},"author":2,"featured_media":2073,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[89,848,307,314,333,939,959],"tags":[],"class_list":["post-2072","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical-trials","category-ivermectin","category-medications","category-meta-analysis","category-mortality-morbidity","category-safety-studies","category-statistics"],"_links":{"self":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/2072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2072"}],"version-history":[{"count":0,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/posts\/2072\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=\/wp\/v2\/media\/2073"}],"wp:attachment":[{"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cov19longhaulfoundation.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}